Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Media-aandacht

• Titel	Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION
  Mate van erkenning	International
  Media naam/outlet	Bio Med Central
  Mediatype	Other
  Release datum	19/08/2022
  Producent / auteur	Jan Kloka1†, Benjamin Friedrichson1†, Stephanie Dauth2,3, Ann Christina Foldenauer2, Anita Bulczak‐Schadendorf2, Maria J. G. T. Vehreschild4, Francisco Maio Matos5, Antoni Riera‐Mestre6,7,8, Antoinette D. I. van Asselt9, Edoardo De Robertis10, Vilma Traskaite Juskeviciene11, Patrick Meybohm12, Dana Tomescu13, Karine Lacombe14, Coen D. A. Stehouwer15,16, Kai Zacharowski1* and on behalf of the IXION Collaboration Group
  URL	trialsjournal.biomedcentral.com/track/pdf/10.1186/s13063-022-06609-x
  Personen	René van Hulst